Catalog No.
Product Name
Application
Product Information
Citations
-
TTK/Mps1 Inhibitor
Luvixasertib hydrochloride is a highly selective inhibitor of TTK/Mps1, demonstrating an IC50 of 1.7 nM for TTK in vitro. This compound exhibits significant anti-cancer activity, making it a valuable tool for cancer research. Its mechanism of action targets crucial mitotic processes, providing insights into cell cycle regulation and tumorigenesis. Luvixasertib hydrochloride is suitable for studies focused on cancer biology and therapeutic development. -
MPS1 Inhibitor
CFI-401980 is a selective inhibitor of the MPS1 kinase, exhibiting an affinity characterized by a Ki value of 0.8 nM. This compound effectively inhibits the proliferation of HCT116 cancer cell lines, making it a valuable tool in cancer research. CFI-401980 may be utilized to investigate the role of MPS1 in cell cycle regulation and its potential as a therapeutic target in anti-cancer strategies. -
Mps1 Inhibitor
TC-Mps1-12 is a highly selective inhibitor of monopolar spindle 1 (Mps1), demonstrating an IC50 of 6.4 nM. It effectively disrupts the function of Mps1, a key regulator of the mitotic spindle assembly checkpoint. This compound is valuable for studying cell cycle regulation, mitosis, and cancer biology, facilitating research into potential therapeutic targets for cancer treatment. -
TTK Inhibitor
NTRC 0066-0 is a potent inhibitor of threonine-tyrosine kinase (TTK), exhibiting an IC50 of 0.9 nM. This selective inhibitor is valuable for cancer research, offering insights into TTK-mediated signaling pathways and their role in tumorigenesis. NTRC 0066-0 enables the exploration of TTK's contribution to cell cycle regulation and cancer cell proliferation. -
MPS1 Inhibitor
Mps1-IN-7 is a potent inhibitor of MPS1 with an IC50 value of 0.020 μM, demonstrating selectivity over JNK1 and JNK2 (IC50 values of 0.11 μM and 0.22 μM, respectively). This compound exhibits significant antiproliferative effects across various cancer cell lines, including SW620, CAL51, Miapaca-2, and RMG1, with GI50 values of 0.065, 0.068, 0.25, and 0.110 μM, respectively. Mps1-IN-7 can be utilized in research focused on cell cycle regulation and the development of targeted cancer therapies. -
MPS1/TTK Inhibitor
RMS-07 is a covalent inhibitor of Monopolar Spindle Kinase 1 (MPS1/TTK), exhibiting an apparent IC50 of 13.1 nM. It selectively targets a poorly conserved cysteine residue within the kinase's hinge region. This compound is utilized in research applications focusing on cell cycle regulation, mitotic checkpoint studies, and cancer therapeutics. -
Mps1 Inhibitor
Mps1-IN-3 hydrochloride is a potent and selective inhibitor of Mps1, with an IC50 value of 50 nM. This compound effectively inhibits the proliferation of glioblastoma cells and enhances the sensitivity of glioblastomas to Vincristine in orthotopic glioblastoma xenograft models. Mps1-IN-3 hydrochloride is valuable for research applications targeting cell cycle regulation and glioblastoma treatment strategies. -
Mps1 Inhibitor
Mps1-IN-10 is a potent inhibitor of Mps1, exhibiting an IC50 of 6.4 nM. This compound effectively suppresses the proliferation of cancer cells, demonstrated by a GI50 of 11 nM in the MDA-MB-231 cell line. Mps1-IN-10 also shows significant anti-tumor efficacy in preclinical models using MDA-MB-231 xenografts, making it a valuable tool for cancer research applications focused on cell cycle regulation and tumor growth inhibition. -
TTK Inhibitor
TTK Inhibitor 3 is a highly potent and selective inhibitor of TTK, a critical enzyme involved in the spindle assembly checkpoint. With an IC50 value of 3.0 nM, this compound effectively disrupts TTK activity, making it a valuable tool for studying cell cycle regulation and mitotic progression. Its application extends to research focused on cancer biology, particularly in the context of therapeutic approaches targeting aberrant cell division. -
Mps1 Inhibitor
Mps1-IN-1 dihydrochloride is a potent ATP-competitive inhibitor of Mps1 kinase, exhibiting an IC50 of 367 nM. This compound effectively inhibits Mps1 mitotic kinase activity, disrupting spindle assembly checkpoint (SAC) function and leading to compromised cell cycle regulation. Mps1-IN-1 dihydrochloride demonstrates cytotoxic effects in various cellular contexts, impacting both cancerous and normal cells, making it a valuable tool for research in cell division and cancer therapy. -
Mps1 Inhibitor
Mps1-IN-6 is a selective inhibitor of Mps1, exhibiting an IC50 value of 2.596 nM. This compound demonstrates significant antiproliferative effects and shows potential as an effective antitumor agent. Mps1-IN-6 is valuable for research into tumor biology and potential therapeutic interventions targeting mitotic checkpoint regulation. -
Mps1 Inhibitor
Mps1-IN-4 is a selective inhibitor of Monopolar spindle 1 (Mps1), a critical kinase involved in the regulation of the mitotic checkpoint. This compound exhibits antiproliferative activity, making it a valuable tool for cancer research. Mps1-IN-4 can be utilized to investigate the role of Mps1 in cell cycle regulation and its implications in tumorigenesis. -
TTK Inhibitor
TTK inhibitor 4 is a potent inhibitor of threonine tyrosine kinase (TTK), exhibiting an IC50 value of 0.016 μM. This compound demonstrates significant anti-tumor activity, making it a valuable tool for cancer research. It is particularly relevant for studies focused on cell proliferation, apoptosis, and signal transduction pathways associated with malignancies. -
Mps1 Inhibitor
Mps1-IN-8 is a potent inhibitor of the Mps1 kinase, a key regulator of the spindle assembly checkpoint. It effectively impairs Mps1 activity, leading to mitotic disruption in cancer cells. This compound is valuable for investigating the role of Mps1 in tumorigenesis and exploring its potential as a therapeutic target in cancer research. -
TTK Inhibitor
CFI-400936 is a potent inhibitor of the TTK protein kinase, demonstrating an IC50 of 3.6 nM. This compound exhibits significant antitumor activity, making it valuable for research focused on cancer treatment and cellular proliferation studies. Its ability to modulate TTK activity positions it as a useful tool for investigating therapeutic strategies in oncology. -
Mps1 Inhibitor
ONCOII is a potent Mps1 inhibitor with an IC50 of 10.8 nM, primarily targeting the Mps1 kinase involved in cell division and checkpoint regulation. This reagent's efficacy is influenced by specific mutations in the Mps1 gene, as cells harboring such mutations show increased resistance to ONCOII. It is particularly useful in cancer research to study cell cycle dynamics and the effects of Mps1 modulation in tumorigenesis. -
MPS1 Inhibitor
Mps-BAY2b is a potent inhibitor of monopolar spindle 1 (MPS1) with an IC50 of 14 nM in human MPS1. This compound demonstrates significant anticancer activity, making it a valuable tool for cancer research. Mps-BAY2b can be utilized in studies to investigate cell cycle regulation and the mechanisms of tumor progression. -
Mps1 Inhibitor
Mps1/TTK-IN-1 is a potent Mps1 kinase inhibitor that specifically binds to the ATP-binding pocket of the enzyme with an IC50 of 9.2 nM and a Kd of 1.6 nM. It effectively inhibits Mps1 activity, including in drug-resistant mutants (C604Y and C604W) with IC50 values of 170 nM and 19 nM, respectively. By blocking the phosphorylation of the kinetochore protein KNL1, Mps1/TTK-IN-1 disrupts spindle assembly checkpoint function and hinders proper chromosome separation, ultimately inhibiting mitosis and tumor cell proliferation, making it a valuable tool for cancer research. - Combretastatin A4 is an antitumor, antiangiogenic and antimetastatic agent, in vitro and in vivo. Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.
-
allosteric PAK1 inhibitor
NVS-PAK1-1 is a potent and selective allosteric PAK1 inhibitor with an IC50 of 5 nM. -
PKC inhibitor
GF 109203X is a potent and selective inhibitor of protein kinase C, selective for the α and β1 isoforms (IC50 values are 0.0084, 0.0180, 0.210, 0.132, and 5.8 μM for α, β1, δ, ε and ζ isoforms respectively). Selective over MLCK, PKG and PKA (IC50 values are 0.6, 4.6, and 33 μM respectively). Potent antagonist at the 5-HT3 receptor (Ki = 29.5 nM). -
microtubule depolymerizing agent
Ansamitocin P-3 is a maytansine analog which displays potent cytotoxicity against the human solid tumor cell lines A-549 and HT-29. -
gap-junction modulator
Tonabersat is a novel benzopyran derivative that blocks the cortical spreading depression proposed to be associated with migraine attacks. -
PAK4 inhibitor
PF-3758309 is a small-molecule p21-activated kinase inhibitor inhibiting oncogenic signaling and tumor growth. -
PKA, PKG, Casein Kinase I and II inhibitor
A-3 Hydrochloride is an inhibitor of PKA (cAMP-dependent protein kinase, Ki=4.3μM) and cGMP-dependent protein kinase, Ki=3.8μM, PKC (protein kinase C, Ki=47μM), casein kinase I and II, and MLCK (myosin light chain kinase) ( Ki=7.4μM). -
microtubule dynamics inhibitor
Vinblastine sulfate inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer. - Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A.
-
Integrin agonist
Leukadherin 1 is an allosteric activator of CD11b/CD18. Increases CD11b/CD18-dependent cell adhesion to fibrinogen (EC50 = 4 μM). -
Mps1 inhibitor
MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 - Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
-
tubulin polymerization inhibitor
Crolibulin, also known as EPC2407 and crinobulin, is a small molecule tubulin polymerization inhibitor with potential antineoplastic activity. -
α4β1/α9β1 inhibitor
R-BC154 is a high affinity fluorescent α4β1/α9β1 inhibitor. -
GpIIb/IIIa antagonist
GR 144053 trihydrochloride is a potent and selective platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist. -
glycoprotein IIb/IIIa antagonist
Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd = 120 nM) that inhibits platelet aggregation.
